Aptus Pharma Limited will host a group meeting with investors and analysts in Mumbai on September 18, 2026. The session is scheduled from 4:00 pm to 6:00 pm.

The company issued the intimation on September 12, 2026, pursuant to Regulation 30 (6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management will conduct the interaction based strictly on publicly available information.

Meeting Details

Tejash Hathi, Managing Director of Aptus Pharma Limited, signed the disclosure. The company noted that changes to the schedule may occur due to exigencies on the part of participants or the company.

Aptus Pharma has approved a ₹44.88 crore preferential allotment of equity shares to fund its transition from a marketing-led model to an integrated pharmaceutical enterprise with in-house manufacturing capabilities. The Board of Directors finalized the pricing during its meeting on Monday, August 17, 2026, based on a valuation report by Registered Valuer CS Amrish N. Gandhi with a relevant date of August 14, 2026.

The company plans to utilize ₹25 crore for capital expenditure, including land acquisition and plant structure, ₹10 crore for working capital requirements, and ₹9.88 crore for general corporate purposes such as debt reduction and strategic growth. These proceeds are proposed to be utilized within 36 months from receipt. The initiative aims to meet approximately 20% of product requirements through in-house manufacturing, strengthening control over quality and supply chains.

Allotment Details and Investor Profile

The preferential issue involves the allotment of 16,02,870 equity shares to 190 investors at ₹280 per share. This final count is slightly lower than the initial 192 investors identified in the intimation dated August 12, 2026. The diverse investor base includes individuals, Hindu Undivided Families (HUFs), and private limited companies.

Post-Issue Shareholding Pattern

The pre-issue aggregate shareholding of the listed allottees was 5,33,800 shares, representing 3.11% of the company's equity capital. Following the allotment, their combined holding increases to 8,43,980 shares, or 4.50%.

Strategic Expansion Plans

Beyond manufacturing, Aptus Pharma intends to strengthen its sales and distribution presence across West, Central, East, and South India to achieve broader Pan-India operations. The company also plans to explore opportunities in select international markets, including Africa, the Middle East, and Latin America, through product registrations and export partnerships. These expansions are subject to commercial viability and regulatory approvals.

Corporate Governance and AGM

The Board took on record compliance certificates from the Practicing Company Secretary (PCS) and the Statutory Auditor regarding the preferential issue under SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and Sections 42 and 62 of the Companies Act, 2013. The proposal is subject to approval by members at the 16th Annual General Meeting (AGM) scheduled for Monday, September 14, 2026, via Video Conferencing or Other Audio-Visual Means.

In compliance with SEBI's Insider Trading Regulations, the trading window for designated persons remains closed until 48 hours after the dissemination of the board meeting outcome to the stock exchanges. The intimation was signed by Tejash Maheshchandra Hathi, Managing Director of Aptus Pharma Ltd.